VEGFA and wet macular degeneration: A proof-of-concept-study for anti- vascular endothelial growth factor (VEGF) expression by the activating ligand tetracycline in a wet AMD mouse model demonstrated the feasibility of the riboswitch in ocular gene therapy [179].